RxDoctor Payments Data

Sarette Kelley, PA

Medical · Mount Pleasant, SCNPI 1760804256

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 282 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations.

$5,003in general payments, 2019–2025

Across 282 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$640
  • Pfizer$517
  • Novo Nordisk$481
  • Amgen$390
  • Boehringer Ingelheim$297
  • Novartis$224
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$5,003100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,003 in reported general payments places this provider in the 85th percentile of 384 medical providers in South Carolina.

See all medical providers in South Carolina

Medicare billing

Part B allowed, 2024
$49,072
Medicare patients
212
Services billed
1,012

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$140,503
EliquisApixaban59$60,129
JardianceEmpagliflozin30$38,262
MounjaroTirzepatide27$30,177
FarxigaDapagliflozin Propanediol20$19,734
TrulicityDulaglutide19$19,676
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$16,276
RybelsusSemaglutide12$14,885
Synjardy XrEmpagliflozin/Metformin Hcl11$11,967
EntrestoSacubitril/Valsartan14$9,148
Breo ElliptaFluticasone/Vilanterol14$5,794
Levothyroxine Sodium219$3,695
Rosuvastatin Calcium189$3,496
Atorvastatin Calcium284$2,848
Omeprazole161$2,435

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$481$155,38994 claims
PfizerEliquis$517$60,12959 claims
Boehringer IngelheimJardiance, Synjardy Xr$297$50,22941 claims
Lilly USA, LLCMounjaro, Trulicity$183$49,85346 claims
GSKTrelegy Ellipta, Breo Ellipta$137$22,07028 claims
AstraZenecaFarxiga$206$19,73420 claims
NovartisEntresto$224$9,14814 claims
AbbVieSynthroid$640$1,54332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 384 medical providers in South Carolina.

Other medical in Mount Pleasant

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →